Shockwave Medical, Inc. (NASDAQ:SWAV) Insider Isaac Zacharias Sells 4,000 Shares

Shockwave Medical, Inc. (NASDAQ:SWAV) insider Isaac Zacharias sold 4,000 shares of the business’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $287.67, for a total transaction of $1,150,680.00. Following the transaction, the insider now owns 56,818 shares in the company, valued at $16,344,834.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Isaac Zacharias also recently made the following trade(s):

• On Monday, February 26th, Isaac Zacharias sold 4,000 shares of Shockwave Medical stock. The shares were sold at an average price of $260.36, for a total transaction of $1,041,440.00.
• On Friday, January 26th, Isaac Zacharias sold 4,000 shares of Shockwave Medical stock. The shares were sold at an average price of $224.69, for a total transaction of $898,760.00.

Shockwave Medical Price Performance

Shares of Shockwave Medical stock opened at $322.61 on Thursday. The company has a quick ratio of 10.73, a current ratio of 11.76 and a debt-to-equity ratio of 1.09. The company has a market cap of $12.07 billion, a PE ratio of 83.36, a P/E/G ratio of 2.67 and a beta of 0.90. The business has a 50 day moving average of $252.72 and a 200 day moving average of $214.63. Shockwave Medical, Inc. has a 52 week low of $157.00 and a 52 week high of $329.08.

Shockwave Medical (NASDAQ:SWAV) last released its earnings results on Thursday, February 15th. The company reported $1.16 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.24. Shockwave Medical had a return on equity of 23.97% and a net margin of 20.17%. The firm had revenue of $202.98 million for the quarter, compared to analysts’ expectations of $199.43 million. During the same period in the prior year, the firm posted $3.71 earnings per share. The company’s quarterly revenue was up 41.0% on a year-over-year basis. As a group, equities research analysts forecast that Shockwave Medical, Inc. will post 4.89 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SWAV. Needham & Company LLC increased their target price on shares of Shockwave Medical from $260.00 to $286.00 and gave the stock a “buy” rating in a report on Friday, February 16th. Piper Sandler lifted their price target on shares of Shockwave Medical from $275.00 to $290.00 and gave the company an “overweight” rating in a research report on Friday, February 16th. CL King started coverage on Shockwave Medical in a research note on Wednesday. They set a “buy” rating and a $368.00 price objective on the stock. Morgan Stanley lowered their price objective on Shockwave Medical from $284.00 to $223.00 and set an “overweight” rating on the stock in a research note on Monday, December 4th. Finally, TheStreet raised Shockwave Medical from a “c+” rating to a “b” rating in a report on Thursday, February 15th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Shockwave Medical has a consensus rating of “Moderate Buy” and an average price target of $271.44.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Lindbrook Capital LLC raised its stake in shares of Shockwave Medical by 64.8% in the third quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock worth $30,000 after buying an additional 59 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Shockwave Medical by 297.4% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 155 shares of the company’s stock valued at $31,000 after buying an additional 116 shares in the last quarter. Quarry LP purchased a new position in Shockwave Medical during the 4th quarter valued at approximately $33,000. Asset Management One Co. Ltd. purchased a new position in Shockwave Medical during the 4th quarter valued at approximately $34,000. Finally, Quest Partners LLC purchased a new position in Shockwave Medical during the 4th quarter valued at approximately $41,000. Institutional investors own 95.35% of the company’s stock.

Shockwave Medical Company Profile

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.